January 11, 2017—LOS ANGELES, CA—Insulin Algorithms, Inc., developers of a comprehensive software tool that supports the initiation and titration of every type of insulin, has been registered as a Class I Device by the Medicines & Healthcare Products Regulatory Agency, allowing it to be sold throughout the European Economic Area and in all countries that accept the Conformité Européenne (CE) mark. The software has also been granted a waiver by Health Canada, allowing for its adoption in North America’s second-largest health care market.
High blood sugar in diabetics is the highest risk factor for premature mortality after high blood pressure and smoking. Over 9% of adults in Europe and Canada have diabetes, and 60 million Europeans and 5.7 million Canadians are pre-diabetic. Nearly all people with diabetes eventually need insulin therapy to manage their blood sugar, but there is a chronic and worsening shortage of endocrinology specialists who can analyze blood glucose data and make well-reasoned insulin dose adjustments. Because of this shortage, people with diabetes are prescribed insulin 6-7 years after other treatments fail, and live with high blood sugar levels for years, doing irreversible damage to their health. However, using Insulin Algorithms software, health care professionals of all levels can easily initiate and titrate insulin by reading a patient’s blood glucose monitor and generating a recommendation for an insulin regimen optimized for that patient. The entire process takes less than a minute.
Clinicians in Canada will begin piloting Insulin Algorithms software in early 2017. The software culminates more than 30 years of work by Insulin Algorithms’ renowned Chief Medical Officer and former American Diabetes Association President Mayer B. Davidson, MD. The recipient of the American Diabetes Association’s 2016 Outstanding Physician-Clinician Award, Dr. Davidson is recognized as a pioneer of algorithmic insulin titration. His adjustment protocols have been developed through decades of research and clinical practice, published by the American Diabetes Association, and used manually to achieve dramatic HbA1c reductions in clinical studies with some of the most challenging patient populations.
“A properly adjusted insulin regimen is one of the best ways to reduce the risk of life-threatening and financially burdensome complications caused by diabetes. But the scale of the epidemic has pushed health care systems beyond their resource limit,” Dr. Davidson said. “By increasing access to first-rate insulin therapy, our software can improve health outcomes and reduce lifetime costs of care for people with diabetes not only in Europe and Canada, but in every region of the world affected by the disease.”
About Insulin Algorithms
Insulin Algorithms software allows health care professionals to analyze blood-glucose monitor data and adjust a patient’s insulin regimen in less than a minute, using algorithms that are clinically proven to lower HbA1c levels. The algorithms were developed by Mayer B. Davidson, MD, a former President of the American Diabetes Association and a pioneer in algorithmic insulin titration. Insulin Algorithms software is the only comprehensive dosing solution for all patients and all insulin regimens. www.insulinalgorithms.com